Ken Griffin Neurocrine Biosciences Inc Put Options Transaction History

Citadel Advisors LLC

10 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q4 2024 Feb 14, 2025	SELL	$111.62 - $139.44 $2.42 Million - $3.03 Million	-21,700 Reduced 45.68%	25,800 $3.52 Million
Q3 2024 Nov 14, 2024	BUY	$114.58 - $153.15 $2.22 Million - $2.97 Million	19,400 Added 69.04%	47,500 $5.47 Million
Q2 2024 Aug 14, 2024	BUY	$130.86 - $143.19 $1.82 Million - $1.99 Million	13,900 Added 97.89%	28,100 $3.87 Million
Q1 2024 May 15, 2024	BUY	$130.4 - $143.74 $521,600 - $574,960	4,000 Added 39.22%	14,200 $1.96 Million
Q4 2023 Feb 14, 2024	SELL	$106.07 - $132.76 $2.22 Million - $2.77 Million	-20,900 Reduced 67.2%	10,200 $1.34 Million
Q3 2023 Nov 14, 2023	BUY	$94.02 - $117.1 $159,834 - $199,070	1,700 Added 5.78%	31,100 $3.5 Million
Q2 2023 Aug 14, 2023	BUY	$89.53 - $104.87 $1.76 Million - $2.07 Million	19,700 Added 203.09%	29,400 $2.77 Million
Q1 2023 May 15, 2023	BUY	$94.11 - $123.02 $432,906 - $565,892	4,600 Added 90.2%	9,700 $981,000
Q4 2022 Feb 14, 2023	BUY	$106.72 - $127.06 $10,672 - $12,706	100 Added 2.0%	5,100 $609,000
Q3 2022 Nov 14, 2022	SELL	$92.03 - $107.81 $303,699 - $355,773	-3,300 Reduced 39.76%	5,000 $531,000

655

95.2M

282K

281K

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $11.1B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.